Navigation Links
Cantel Medical Reports EPS of $0.33 vs. $0.30 on 8% Sales Increase for Third Quarter Ended April 30, 2013

LITTLE FALLS, N.J., June 6, 2013 /PRNewswire/ -- CANTEL MEDICAL CORP. (NYSE: CMN) reported a 10% increase in net income to $8,998,000, or $0.33 per diluted share, on an 8% increase in sales to $105,009,000 for the third quarter ended April 30, 2013. This compares with net income of $8,174,000, or $0.30 per diluted share, on sales of $97,238,000 for the third quarter ended April 30, 2012. For the nine months ended April 30, 2013, the Company reported record net income of $29,026,000, or $1.06 per diluted share, inclusive of $0.02 in net favorable adjustments related to acquisition accounting partially offset by severance and recruiting costs, on an 8% increase in sales to a record $311,053,000.  This compares with net income of $21,688,000 or $0.80 per diluted share, inclusive of a $0.02 charge related to an asset impairment, on sales of $287,797,000 for the nine months ended April 30, 2012.

Andrew Krakauer, Cantel's President and CEO stated, "We are pleased to have delivered solid financial performance in the third quarter. These positive results confirm the continued success of our three prong approach to growth which includes investing in new product development, sales and marketing programs and acquisitions. Reported earnings would have been $0.02 better if not for the Medical Device Tax which impacted all three months of this quarter."

Krakauer added, "Performance this quarter was led by our Healthcare Disposables segment. With the benefit of the ongoing integration of the SPS Medical sterility assurance business acquired on November 1, 2012, sales in this segment grew by 17% compared to last year and we were able to offset the negative effect caused by our distributors pulling forward shipments last quarter. Operating profits were 13% higher and grew more slowly than sales as we made substantial investments in sales and marketing expenses. We are very pleased with the performance of SPS Medical and will be investing in additional sales and marketing resources, as well as R&D, to accelerate growth in fiscal year 2014 and beyond.

As in the first two quarters of this fiscal year, our Water Purification and Filtration segment had excellent year-over-year quarterly performance with organic sales growth of almost 14%. Operating profits in this segment were only slightly higher due to increases in selling expenses and transaction expenses associated with our recent acquisition. In our largest business unit, Endoscopy, quarterly sales growth of 3% was driven by our liquid chemical germicides, service and procedural products categories. We remain encouraged with the continued growth prospects for this segment as we continue to launch new products into this multi-billion market segment.  At two major endoscopy trade shows in May, we had a very successful turnout and were encouraged by the customer excitement and feedback on our portfolio of newly launched products."

The Company further reported that its balance sheet at April 30, 2013 included current assets of $145,183,000, including cash of $30,669,000, a current ratio of 2.6:1, debt of $105,000,000 and stockholders' equity of $307,955,000.  Krakauer stated, "The Company has a strong balance sheet and continues to generate significant cash flow and EBITDAS.  When compared with the first nine months of last year, our EBITDAS grew by 19% to $62,806,000.  Net debt was reduced during the quarter by almost $6 million to $74,331,000 despite the approximate $8 million acquisition of the Siemens hemodialysis water business announced on March 25."

Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. 

The Company will hold a conference call to discuss the results for the third quarter ended April 30, 2013 on Thursday, June 6, 2013 at 11:00 AM Eastern time. To participate in the conference call, dial 1-877-407-8033 approximately 5 to 10 minutes before the beginning of the call. If you are unable to participate, a digital replay of the call will be available from Thursday, June 6, 2013 at 2:00 PM through midnight on August 6, 2013 by dialing 1-877-660-6853 and using conference ID #415610.

The call will be simultaneously broadcast live over the Internet on at A replay of the webcast will be available on Vcall for 90 days.

For further information, visit the Cantel website at

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.

 CANTEL MEDICAL CORP. CONDENSED CONSOLIDATED STATEMENTS OF INCOME(In thousands, except per share data)(unaudited)Three Months EndedNine Months EndedApril 30,April 30,2013201220132012Net sales$   105,009$
97,238$   311,053$   287,797Cost of sales59,52554,619176,691166,407Gross profit45,48442,619134,362121,390Expenses:  Selling15,09614,24042,23240,433  General and administrative13,76612,38838,19636,582  Research and development2,3992,2176,8766,660Total operating expenses31,26128,84587,30483,675Income before interest, other expense and income taxes

14,22313,77447,05837,715Interest expense7498972,1862,928Interest income(16)(13)(45)(67)Other expense---605Income before income taxes13,49012,89044,91734,249Income taxes4,4924,71615,89112,561Net income $
21,688Earnings per common share - diluted$
.80Dividends per common share $
.05Weighted average shares - diluted 27,50127,28227,44227,148 CANTEL MEDICAL CORP.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(unaudited)April 30,July 31,20132012AssetsCurrent assets$
33,892Property and equipment, net45,43143,022Intangible assets, net74,16571,311Goodwill208,176183,655Other assets11,4092,932$
434,812Liabilities and stockholders' equityCurrent portion of long-term debt$
,000Other current liabilities46,26045,141Long-term debt95,00080,000Other long-term liabilities 25,14923,735Stockholders' equity307,955275,936$
434,812 SUPPLEMENTARY INFORMATIONReconciliation of Earnings Before Interest, Taxes, Depreciation, Amortization and Stock-BasedCompensation Expense ("EBITDAS")(unaudited)The reconciliation of EBITDAS with net income for the three and nine months ended April 30, 2013 and 2012,respectively, is as follows (in thousands):Three Months EndedNine Months EndedApril 30,April 30,2013201220132012Net income$
21,688Income taxes4,4924,71615,89112,561Interest expense7498972,1862,928Interest income(16)(13)(45)(67)Other expense---605Depreciation1,8061,7355,3805,129Amortization2,5982,2797,4386,846Loss (gain) on disposal of fixed assets(16)5812494EBITDA18,61117,84660,00049,784Stock-based compensation expense9197062,8063,019EBITDAS$
52,803EBITDAS is a measure of the Company's performance that is not required by, or presented in accordance with,Generally Accepted Accounting Principles ("GAAP"). EBITDAS is a non-GAAP financial measure defined by theCompany as income before interest, taxes, depreciation, amortization and stock-based compensation expense.The Company believes EBITDAS is an important valuation measurement for management and investors giventhe increasing effect that non-cash charges, such as stock-based compensation, amortization related to acquisitionsand depreciation of capital equipment, has on the Company's net income. In particular, acquisitions have historicallyresulted in significant increases in amortization of intangible assets that reduced the Company's net income.Additionally, the Company regards EBITDAS as a useful measure of operating performance and cash flow beforethe effect of interest expense and complements operating income, net income and other GAAP financial performance measures. Generally, a non-GAAP financial measure is a numerical measure of a Company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. This measure, however, should be considered in addition to, and not as a substitute or superior to, net income, cash flows, or other measures of financial performance prepared in accordance with GAAP.

SOURCE Cantel Medical Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cantel Medical Corp. To Hold Conference Call To Discuss Results for Its Third Quarter Ended April 30, 2013
2. Cantel Medical To Present At The Bank Of America Merrill Lynch Health Care Conference
3. Cantel Medical To Present At Needham 12th Annual Healthcare Conference
4. Cantel Medicals Mar Cor Purification Subsidiary Acquires Hemodialysis Water Business from Siemens Water Technologies Business Unit
5. Cantel Medical Reports EPS of $0.38 vs. $0.27 on 9% Sales Increase for Second Quarter Ended January 31, 2013
6. Cantel Medical Reports EPS of $0.35 vs. $0.23 for First Quarter Ended October 31, 2012
7. Cantel Medical Appoints Jorgen B. Hansen As Executive Vice President And Chief Operating Officer
8. Cantel Medical Corp. To Present At The CL King 10th Annual Best Ideas Conference
9. Cantel Medical Board Of Directors Authorizes Regular Semiannual Dividend
10. Inspiro Medical Ltd. Completes a Successful First Clinical Trial in Asthmatic Children
11. Frost & Sullivan: Standardized Regulations Crucial for Growth in Global Dimensional Metrology Market for Medical Devices
Post Your Comments:
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Global Surgical Drainage ... are tubes used to remove excess liquid and air. ... pus, urine, bile or lymph. Surgical drains are used ... such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery ... post-surgery to prevent accumulation of fluid e.g. blood or ...
Breaking Medicine Technology:
(Date:4/30/2017)... Viejo, CA (PRWEB) , ... April 30, 2017 ... ... animations created exclusively for use in Final Cut Pro X. Editors can pick ... and more. Easily change the highlights, mid levels and shadows using simple color ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of ... video to the next without having to set a single keyframe in Final ... enhance your video production. , TransDark features dynamic transitions that momentarily splits the RGB ...
(Date:4/28/2017)... ... April 28, 2017 , ... An April 24th article on Yahoo! Beauty ... pounds with the help of a weight loss surgery. The woman, declaring “I will not ... have been left following her dramatic weight loss. Dr. Feiz & Associates notes that, while ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio America proudly introduces ... an instant energy-saving solution for F32T8 fluorescent lamps on most instant-start and programmed-start ... 50,000 hour rated lamps utilize the existing electronic ballast, saving labor and maintenance ...
Breaking Medicine News(10 mins):